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ABSTRACT
Objective: To determine the prevalence of vitamin D deficiency (VDD) in exclusively breastfed 
infants at the Aga Khan University Hospital Nairobi, Kenya (AKUHN). The relationships between 
25-hydroxyvitamin D; 25OHD, parathyroid hormone (PTH), maternal vitamin D supplementation, and 
sunlight exposure were also determined. Subjects and methods: Blood from 98 infants was assayed 
for 25OHD, calcium, phosphate, and PTH. Socio-demographic and clinical characteristics were 
analyzed using descriptive statistics and inferential analysis  (p < 0.05). Results: The prevalence of 
VDD (25OHD <12 ng/mL), vitamin D insufficiency (VDI, 25OHD 12-20 ng/mL) and vitamin D sufficiency 
(VDS, 25OHD >20 ng/mL) was 11.2% (95% CI 8.0%-14.4%), 12.2% (95% CI 8.9%-15.5%), and 76.5% 
(95% CI 72.3%-80.8%) respectively. There was no difference in the mean age, head circumference, 
length, or weight of infants in VDD, VDI, and VDS groups. PTH was elevated when 25OHD was 
<12 ng/mL and normal when 25OHD was between 12-20 ng/mL. 25OHD and PTH were normal in 
infants whose mothers received vitamin D supplements. Infants who received <30 minutes/day of 
exposure to sunlight were 5 times more likely to have VDI than infants who received ≥30 minutes/day 
(p = 0.042). Conclusions: The prevalence of VDD in exclusively breastfed infants at AKUHN is low. 
The current national policy that recommends exclusive breastfeeding of infants in the first 6 months 
of life appears to be effective in staving off vitamin D deficiency but those infants with < 30 minutes 
sunlight exposure may benefit from low dose supplemental vitamin D during times of low sunlight 
exposure. 
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INTRODUCTION
Vitamin D is a fat-soluble steroid hormone that is produced when the skin is exposed to sunlight 
(1). It is involved in the reduction of inflammation, 
modulation of cell growth, normal functioning 
of the nervous and immune systems, and bone 
metabolism (2). The human body obtains >80% 
of vitamin D when ultraviolet-B radiation (UV-B) 
converts 7-dehydrocholesterol in epidermal and 
dermal cells to 25-hydroxyvitamin D; 25OHD (3,4). 
This metabolite is subsequently hydroxylated in the 
liver and kidney to form 1,25-dihydroxyvitamin D; 
1,25(OH)2D (3,4). Vitamin D (~20%) may also be 
supplied via the diet (3,4). 
25OHD has a long half-life in the circulation 
and its concentration is not under tight homeostatic 
regulation (5,6). It is therefore useful for measuring 
the levels of vitamin D in the human body (5,6). It 
may be assayed by chromatographic, spectroscopic, or 
immunosorbent techniques including high-pressure 
liquid chromatography, liquid chromatography-
tandem mass spectroscopy, radioimmunoassays, and 
competitive protein binding assays (7). The analysis and 
interpretation of 25OHD is made by using thresholds 
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of <12 ng/mL, 12-20 ng/mL, and >20 ng/mL to 
denote vitamin D deficiency, vitamin D insufficiency and 
vitamin D sufficiency respectively in keeping with the 
recommendations of several global health authorities 
including the American Institute Of Medicine (IOM), 
the UK Scientific Advisory Committee on Nutrition 
(SACN), the Nordic Nutritional Recommendations 
(NNR), and the European Food Safety Authority 
(EFSA) (8-11). 
Severe VDD causes osteomalacia in adults and rickets 
in children (12-14). However, because vitamin D is 
physiologically involved in other body systems, health 
impacts such as osteoporosis, breast cancer, and pre-
eclampsia may also be realized (12-14). Estimates 
suggest that up to a billion people are affected by VDD 
and VDI worldwide (15). Exclusively breastfed infants 
are particularly vulnerable to VDD and maternal VDD 
during pregnancy has been identified as one of the major 
contributors of VDD in infants (16). For example, at 
AKUHN, eight out of every ten-term newborn infants 
are born to vitamin-D-deficient mothers (16). 
The National Nutrition Action Plan is a policy in 
Kenya that recommends the exclusive breastfeeding 
of infants until they are six months of age (17). 
While breastfeeding is the recommended method of 
infant feeding and provides infants with the necessary 
nutrients and immune factors, breast milk provides only 
about 10-80 IU/L of vitamin D which is short of the 
recommended 400 IU and is likely to result in VDD 
(18). By evaluating the prevalence of VDD among 
exclusively breastfed infants in the region, the scope 
of VDD as a public health problem can be realized. 
Presently, this data is not available. This study, therefore, 
aims to fill this gap by determining the prevalence of 
VDD among exclusively breastfed infants at AKUHN, 
a private referral hospital in Nairobi, Kenya. The 
relationship between 25OHD, PTH, maternal vitamin 
D supplementation, and sunlight exposure was also 
determined.
SUBJECTS AND METHODS
Study setting
The Aga Khan University Hospital (AKUHN) is a 
private referral hospital that serves residents of Nairobi 
and the wider East African region (19). This institution 
offers both outpatient and inpatient pediatric services 
(19). A well-baby clinic is also available which provides 
immunization services and growth monitoring for 
infants and children under the age of five years (19). 
On average, 30 infants aged three to six months are 
seen at the hospital per week (19).
Ethical considerations
Ethical approval was sought from the ethics committee 
at the Aga Khan University Hospital; AKUHN (REF: 
2014/REC-23 (v2); Supplementary data; Appendix I). 
The purpose of the study was carefully explained to all 
the mothers of participating infants and an opportunity 
was provided to them to seek clarifications regarding 
the study. Mothers were requested to sign an informed 
consent form detailing the terms of participation 
(Supplementary data; Appendix II). Mothers were free 
to withdraw their child from the study at any time. 
In keeping with the guidelines of the Department of 
Pediatrics at AKUHN, routine blood sampling was 
usually done for all infants at six months of age to 
determine their hemoglobin levels. For these infants, 
sampling for this study was done at the same time to 
avoid multiple pricks. EMLA® (lidocaine) cream, a 
topical anesthetic agent was applied at the sampling site 
to minimize pain. Tests were carried out at no cost to 
the patients. Confidentiality was maintained by using 
codes instead of personal identifying information. 
Study design
This was a cross-sectional study to determine the 
prevalence of vitamin D deficiency in exclusively 
breastfed infants at the Well-Baby Clinic of the 
Aga Khan University Hospital, Nairobi (AKUHN) 
between October 2014 and April 2015. Infants who 
fit the following characteristics were included in the 
study: a) term (>37 weeks gestational age at birth) 
singleton infants aged three to six months old, b) 
exclusively breastfed infants, and c) informed consent 
was obtained from the parent to participate in the 
study. Preterm infants, those receiving Vitamin D 
supplements, those with kidney/liver, parathyroid or 
bone diseases or malabsorption syndromes and infants 
on medication known to alter vitamin D metabolism 
(anticonvulsants, anti-tubercular drugs, antifungals, 
and antiretrovirals) were excluded from the study. A 
flow chart showing the criteria of recruiting infants at 
the Aga Khan University Hospital Nairobi, Kenya is 
summarized in Figure 1. 
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Sample size estimation
Fischer’s formula was used to calculate the sample 
size (20). 
 i.e. N= Z2 P (1-P)
  D2
Where;
N = minimum sample size
Z = standard normal deviation corresponding to 95% confidence interval  
(= 1.96) in a 2-tailed test.
P = the expected proportion (50%)
D = degree of precision (10%)
N = 96
The expected proportion was estimated at 50% 
to give the largest sample size with a 10% degree of 
precision. The choice of the degree of precision value 
of 10% was due to financial and time limitations.
Sampling technique
All three to six-month-old infants visiting the well-baby 
clinic from October 2014 were evaluated for eligibility. 
Recruitment continued until the desired sample 
size was achieved; April 2015. A focused physical 
examination was done on each of the recruited infants 
to assess for skeletal signs of rickets. The outcome of 
the examination was recorded in a pre-designed form 
(Supplementary data; Appendix III) that was coded 
for each participant. This remained in the custody of 
the principal investigator. The phlebotomy site was 
identified, swabbed with alcohol, and a sample of 
2 mL of blood was drawn from a vein and collected in 
standard sampling tubes (clear red-topped vacutainers). 
The specimen bottle for each participant bore the same 
unique code as the recruitment form with the patient’s 
details. Blood samples were sent to the laboratory and 
analyzed daily. 
ELECSYS 25OHD total assay 
Reagents – Working solutions
The reagent rack pack (M, R1, and R2) and the 
pretreatment reagents (PT1, and PT2) were labeled 
as VITD-T. PT1 Pretreatment reagent 1 (white cap), 
1 bottle, 4 mL: Dithiothreitol 1 g/L, pH 5.5. PT2 
Pretreatment reagent 2 (gray cap), 1 bottle, 4 mL: 
Sodium hydroxide 55 g/L. M Streptavidin-coated 
microparticles (transparent cap), 1 bottle, 6.5 mL: 
Streptavidin-coated microparticles 0.72 mg/mL; 
preservative. R1 Vitamin D binding protein-BPRu 
(gray cap), 1 bottle, 9 mL: Ruthenium labeled 
vitamin D binding protein 150 μg/L; bis-tris propane 
buffer 200 mmol/L; albumin (human) 25 g/L; pH 7.5; 
preservative. R2 25-hydroxyvitamin D~biotin (black 
cap), 1 bottle, 8.5 mL: Biotinylated vitamin D (25-OH) 
14 μg/L; bis-tris propane buffer 200 mmol/L; pH 
8.6; preservative (21).
Assay
A Cobas analyzer (Roche, Mannheim, Germany) 
was used for these measurements according to 
manufacturers’ protocols (21). The assay involved a 
3-step incubation process, over a 27-minute duration 
(21). In the first step, the sample was incubated with 
pretreatment reagent, which released bound 25-OH 
vitamin D from the vitamin D binding protein (VDBP) 
(21). In step 2, the pretreated sample was incubated 
with ruthenium labeled VDBP creating a complex 
between the 25-OH vitamin D and the ruthenylated 
VDBP (21). The third incubation step involved the 
addition of streptavidin-coated microparticles and 
25-OH vitamin D labeled with biotin (21). The free 
sites of the ruthenium labeled VDBP become occupied, 
forming a complex consisting of the ruthenium labeled 
vitamin D binding protein and the biotinylated 
25-OH vitamin D (21). The entire complex then 
becomes bound to the solid phase via interaction of 
biotin and streptavidin (21). The reaction mixture 
was then aspirated into the measuring cell where the 
microparticles were magnetically captured onto the 
Figure 1. Flow chart showing the criteria of recruiting infants at the Aga 
Khan University Hospital Nairobi, Kenya.
Participants assessed 
for eligibility (n = 180) Ineligible participants 
(n = 72):
Not exclusively 
breastfed (n = 40)
Not within the age 
limit (n = 28)
2 sets of twins (n = 4)
Eligible and consented 
(n = 108)
Insufficient volume of 
the samples (n = 3)
Incomplete data 
(n = 2)
Data collected and 
blood samples drawn 
(n = 103)
Final number of 
participants (n = 98)
Refusals and difficult 
blood draws (n = 5)
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
4
VDD in exclusively breastfed infants
Arch Endocrinol Metab. 
surface of the electrode (21). Unbound substances were 
then removed with ProCell/ProCell M. Application of 
a voltage to the electrode induced a chemiluminescent 
emission which was measured by a photomultiplier 
(21). Results were determined via a calibration curve 
which was instrument specifically generated by 2-point 
calibration and a master curve provided via the reagent 
barcode (21). 25OHD was reported in nanograms per 
milliliter (ng/mL) (21).  
ELECSYS PTH assay
Reagents – Working solutions
The reagent rack pack was labeled as PTH (22). 
Streptavidin-coated microparticles (transparent cap), 
1 bottle, 6.5 mL: Streptavidin-coated microparticles 
0.72 mg/mL; preservative. R1 Anti-PTH Ab~biotin 
(gray cap), 1 bottle, 7 mL: Biotinylated monoclonal 
anti-PTH antibody (mouse) 2.3 mg/L; phosphate 
buffer 100 mmol/L, pH 7.0; preservative. R2 Anti-
PTH-Ab~Ru(bpy) (black cap), 1 bottle, 7 mL: 
Monoclonal anti-PTH antibody (mouse) labeled with 
ruthenium complex 2.0 mg/L; phosphate buffer 100 
mmol/L, pH 7.0; preservative (22). 
Assay
A Cobas analyzer (Roche, Mannheim, Germany) 
was used for these measurements according to 
manufacturers’ instructions (22). The assay involved a 
2-step incubation process, over an 18-minute duration 
of time (22). Step 1 involved incubating 50 μL of 
the sample, a biotinylated monoclonal PTH-specific 
antibody, and a monoclonal PTH-specific antibody 
labeled with a ruthenium complex to form a sandwich 
complex (22). Step 2 involved the addition of 
streptavidin-coated microparticles, and the complex 
became bound to the solid phase via the interaction 
of biotin and streptavidin (22). The reaction mixture 
was then aspirated into the measuring cell where the 
microparticles were magnetically captured onto the 
surface of the electrode (22). Unbound substances were 
then removed with ProCell/ProCell M. Application of 
a voltage to the electrode induced chemiluminescent 
emission which was measured by a photomultiplier 
(22). Results were determined via a calibration curve 
which was instrument generated by 2-point calibration 
and a master curve provided via the reagent barcode 
(22). PTH levels were reported as picograms/milliliter 
(pg/mL) (22). 
Calcium and phosphate assay
A Cobas analyzer (Roche, Mannheim, Germany) which 
uses the electrochemiluminescence (ECLIA) assay 
principle was used for these measurements (23,24). The 
precision of this analyzer is summarized in (Appendix 
VI and VII).
Data handling and analysis 
The collected data were entered into Microsoft Excel®. 
25OHD, calcium, phosphate, and PTH were analyzed 
by descriptive statistics. Proportions were used in the 
analysis of vitamin D prevalence and the mean levels 
PTH, calcium, and phosphate in the VDD, VDI, and 
VDS groups were compared by One Way Analysis of 
Variance (ANOVA) and Bonferroni test as post hoc 
test. The relationship between PTH and 25OHD was 
determined by scatter plot analysis and odds ratio was 
used to determine the relationship between infant serum 
25OHD and maternal vitamin D supplementation and 
sunlight exposure. p<0.05 was considered significant in 
all cases. GenStat 15th edition and SPSS version 20.0 
were used. 
RESULTS
Socio-demographics of the study participants
The mean age of the recruited infants was 4.6 months. 
54.1% (53/98) were male and 45.9% (45/98) were 
female. 
Prevalence of vitamin D deficiency
The prevalence of vitamin D deficiency (25OHD 
<12 ng/mL) among exclusively breastfed infants at 
AKUHN was 11.2% (95% CI: 8.0%-14.4%), and 12.2% 
(95% CI: 8.9%-15.5%) were found to have insufficient 
levels (12 ng/mL to 20 ng/mL) while 76.5% (95% CI: 
72.3%-80.8%) had a sufficient level
Relationship between 25OHD, phosphate, calcium, 
and parathyroid hormone (PTH)
Table 1 is a summary of the mean values of 
sociodemographic and clinical variables of infants at 
the Aga Khan University Hospital, Nairobi. There 
was no significant difference in the mean age, head 
circumference, length, or weight of infants in the 
VDD, VDI, and VDS groups (Table 1). The mean 
phosphate level in the VDD group was significantly 
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Table 1. Summary of the mean values of sociodemographic and clinical variables of infants at the Aga Khan University Hospital
Variable VDD(n:11)
VDI
(n:12)
VDS
(n:75)
Socio demographic variables
Age (months)
Head circumference (cm)
Length (cm)
Weight (cm)
4.3 (1.2)a
43.7 (1.4)a
63.0 (2.2)a
7.6 (1.2)a
4.2 (0.8)a
42.5 (0.7)a
62.5 (2.0)a
6.8 (0.7)a
4.8 (1.0)a
43.0 (1.8)a
63.4 (3.5)a
7.4 (1.2)a
Clinical variables
Calcium (mmol/L)
Phosphate (mmol/L)
25OHD (ng/mL)
PTH (pg/mL)
2.5 (0.2)a
1.6 (0.2)a
7.9 (3.1)a
145.3 (74.6)b
2.6 (0.2)a
2.0 (0.5)b
16.8 (2.3)a
35.5 (13.9)a
2.7 (0.2)a
2.0 (0.2)b
35.8 (11.3)b
37.4 (22.8)a
Values expressed as means and standard deviation. One-Way ANOVA and Bonferroni post hoc test was used. Means with different superscripts across the rows are significantly different at p<0.05. 
VDD: vitamin D deficiency; VDI: vitamin D insufficiency; VDS: vitamin D sufficiency.
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Figure 2. Relationship between 25OHD and serum calcium and phosphate in infants at the Aga Khan University Hospital Nairobi, Kenya.
(p<0.05) lower than the mean levels in the VDI and 
VDS groups (Table 1). The mean parathyroid level 
in the VDD group was significantly (p<0.05) higher 
than the mean levels in the VDI and VDS groups 
(Table 1). There was no significant difference in the 
mean calcium levels of VDD, VDI, and, VDS groups 
(Table 1). There was a positive and direct relationship 
between 25OHD and calcium and phosphate 
(Figure 2). This relationship was more discernible at 
25OHD < 30 ng/mL (Figure 2). PTH was mostly 
elevated when 25OHD was < 12 ng/mL (Figure 3). 
PTH was normal when 25OHD was between 12 ng/mL 
to 20 ng/mL (Figure 3). However 6 infants had 
elevated PTH despite having 25OHD between 20 
and 30 ng/mL (Figure 3). 
0
0
20
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50 100 150 200 250 300
25
OH
D 
(n
g/
m
l)
PTH (pg/mL)
Figure 3. Relationship between 25OHD and PTH in infants at the Aga 
Khan University Hospital Nairobi, Kenya.
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Maternal vitamin D supplementation and rachitic 
manifestations in infants
There were four infants whose mothers were on vitamin D 
supplementation (Figure 4). All of these infants had 
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Figure 4. 25OHD, PTH, calcium, and phosphate in infants at the Aga Khan University Hospital, Nairobi, Kenya whose mothers had vitamin D supplementation.
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sufficient 25OHD and none had elevated PTH. About 
4/98 (4.1%) of the infants manifested skeletal signs of 
rickets. Figure 5 is a summary of the metabolic features 
of infants with skeletal manifestations of rickets. 
Figure 5. Metabolic features of infants with skeletal manifestations of rickets at the Aga Khan University Hospital Nairobi, Kenya
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Relationship between 25OHD and sunlight exposure 
in infants and mothers
Infants with <30 minutes of exposure to sunlight were 
5 times more likely to have vitamin D insufficiency 
than infants who received ≥30 minutes of exposure to 
sunlight (p=0.042) – Table 2. 
DISCUSSION
To the best of our knowledge, this is the first study 
to determine the prevalence of VDD in exclusively 
breastfed infants in the study area. Considering that 
the region receives adequate UV radiation throughout 
the year (25) this prevalence is somewhat unexpected. 
It is plausible that this finding may have something 
to do with the fact that some of the participating 
infants had been born during or before the 3 coldest 
months of the year i.e. July, August, and September 
when temperatures were as low as 9 °C (26). There 
is a tendency for mothers to wrap their babies in 
multiple layers of clothing during harsh (cold) weather 
conditions to keep them warm. This is particularly true 
when the infants are outdoors. Therefore, not only is 
infant sun exposure occluded but also the cutaneous 
synthesis of vitamin D is impaired. 
The prevalence rate we have reported was lower 
than what was reported in a similar study at the Rubaga 
hospital in Kampala, Uganda (27). This observation 
may be the result of differences in policy between the 
two hospitals. Sun exposure is impressed upon mothers 
at discharge from the postnatal unit of AKUHN and 
every well-baby clinic visit thereafter. This is in light of 
findings by Dodia and cols. who observed that there 
was a high prevalence of VDD in newly delivered 
mothers at AKUHN (16). Through this study, the 
cut-off value for VDD in the study area has been 
determined for the first time. The value is within the 
clinical threshold set by various global health authorities 
Table 2. Relationship between exposure to sunlight in infants and mothers and 25OHD in infants at the Aga Khan University Hospital Nairobi, Kenya
Optimal exposure to sunlight
Infants Mothers
Status Odds ratio Confidence intervals p value Odds ratio
Confidence 
intervals p value
VDS 1.0 - - 1.0 - -
VDI 4.98 1.06-23.36 0.04* 0.63 0.15-2.61 0.53
VDD 1.35 0.31-5.73 0.53 0.66 0.15-2.82 0.58
VDS: vitamin D sufficient; VDI: vitamin D insufficient; VDD: vitamin D deficient. * Significant at p<0.05.
including the American Institute of Medicine (IOM), 
the UK Scientific Advisory Committee on Nutrition, 
the Nordic Nutritional Recommendations, and the 
European Food Safety Authority (8-11). 
We observed that infants whose mothers had 
received vitamin D supplementation had normal levels 
of calcium, phosphate, and 25OHD ≥30 ng/mL. This 
suggests that maternal vitamin D supplementation 
during pregnancy and breastfeeding may be beneficial 
in staving off vitamin D deficiency in exclusively 
breastfed infants. 
The finding that even the severely vitamin D-deficient 
infants had serum calcium and phosphate levels that were 
within normal reference limits supports the specification 
of vitamin D deficiency being at 25OHD <12 ng/mL. 
The reference values for parathyroid hormone (PTH) 
in infants is between 9.4 and 66 ng/mL (28). On visual 
inspection parathyroid hormone (PTH) was elevated 
when 25OHD was below 12 ng/mL, and PTH were 
all normal when 25OHD was between 12 ng/mL to 
20 ng/mL. Active vitamin D (calcitriol) facilitates the 
absorption of calcium and phosphorous from the gut 
and its deficiency reduces calcium absorption and serum 
calcium levels, which triggers greater PTH synthesis 
(28). PTH elevation was observed in 6 infants who 
had 25OHD between 20 and 30 ng/mL and normal 
calcium and phosphate. Possible explanations may be 
that there may have been low maternal calcium intake or 
that the infants may have had some renal impairment/
malabsorption syndromes. However, we believe that 
the reduced maternal calcium may be a more likely 
explanation for the PTH elevation. This is because not 
only was there no stunted development of observed 
in infants during physical examination but also part 
of our infant recruitment strategy involved excluding 
infants with kidney/renal impairment, malabsorption 
syndromes, and those on medication known to alter 
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vitamin D metabolism i.e. anticonvulsants, anti-
tubercular drugs, antifungals, and antiretrovirals). 
Less than 5% of study participants had signs of rickets 
(wrist prominence, Harrison’s sulcus, and a rachitic 
rosary). This observation, when taken in the context 
of the 11.2% of infants who had VDD and the 12.2% 
of infants who had VDI suggests that skeletal features 
may be late manifestations of vitamin D deficiency and 
therefore there may be a need to review the use of 
these features in informing clinical decisions relevant to 
vitamin D deficiency. 
In conclusions, our findings suggest that the 
prevalence of VDD among exclusively breastfed 
infants in the study area is low. The current policy that 
recommends the exclusive breastfeeding of infants in 
Kenya until they are six months of age appears to be 
effective in staving of vitamin D deficiency and should 
be promoted in hospitals with similar infrastructure as 
Aga Khan University Hospital, Nairobi. Because of the 
higher risk of vitamin insufficiency in infants with <30 
minutes of sunlight exposure, low dose supplemental 
vitamin D during times of low sunlight exposure may 
be recommended. 
Limitations: sun exposure data collected for this study was self-
-reported and therefore subject to some degree of bias. The 
amount of skin surface area exposed, the use of sunscreens, and 
the amount of cloud cover in the study participants was also not 
determined. All these factors affect the cutaneous synthesis of vi-
tamin D. The PTH cut-offs used were extrapolated from studies 
of the general population, which also includes vitamin D deficient 
individuals, and may therefore not reflect the true cut-off for nor-
mal infants. 
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